Akebia Therapeutics (AKBA) Earnings Date, Estimates & Call Transcripts $2.43 -0.12 (-4.71%) Closing price 04:00 PM EasternExtended Trading$2.42 -0.02 (-0.62%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Akebia Therapeutics Earnings Summary Akebia Therapeutics posted Q1 2025 earnings on May 8, 2025, reporting an EPS of $0.03, which topped the consensus estimate of -$0.03 by $0.06. Quarterly revenue was reported to be $57.34 million, above the consensus estimate of $44.88 million. With a trailing EPS of -$0.21, Akebia Therapeutics' earnings are expected to grow next year, from ($0.30) to ($0.14) per share. Latest Q1 Earnings DateMay. 8EstimatedConsensus EPS (May. 8) -$0.03 Actual EPS (May. 8) $0.03 Beat By $0.06 Actual Revenue (May. 8) $57.34MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Akebia Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akebia Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAKBA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AKBA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Akebia Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.11-$0.01-$0.06Q2 20252-$0.10-$0.02-$0.06Q3 20252-$0.08-$0.03-$0.06Q4 20252-$0.06-$0.01-$0.04 Akebia Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025-$0.03$0.03+$0.06$0.03$44.88M$57.34M3/13/2025Q4 2024-$0.05-$0.10 -$0.05-$0.10$37.36M$46.50M11/7/2024Q3 2024-$0.04-$0.10 -$0.06-$0.10$45.66M$37.43M8/8/2024Q2 2024-$0.06-$0.04+$0.02-$0.04$45.61M$43.65M5/9/2024Q1 2024-$0.09-$0.09--$0.09$41.13M$32.61M3/14/2024Q4 2023-$0.04-$0.04--$55.64M$56.20M11/8/2023Q3 2023-$0.09-$0.08+$0.01-$0.08$48.19M$42.05M8/25/2023Q2 2023-$0.03-$0.06 -$0.03-$0.06$59.10M$56.38M Akebia Therapeutics Earnings - Frequently Asked Questions When did Akebia Therapeutics announce their last quarterly earnings? Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earning data on Thursday, May 8, 2025. Learn more on AKBA's earnings history. Did Akebia Therapeutics beat their earnings estimates last quarter? In the previous quarter, Akebia Therapeutics (NASDAQ:AKBA) reported $0.03 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.03) by $0.06. Learn more on analysts' earnings estimate vs. AKBA's actual earnings. How can I listen to Akebia Therapeutics's earnings conference call? The conference call for Akebia Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Akebia Therapeutics's conference call transcript? The conference call transcript for Akebia Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Akebia Therapeutics generate each year? Akebia Therapeutics (NASDAQ:AKBA) has a recorded annual revenue of $160.18 million. How much profit does Akebia Therapeutics generate each year? Akebia Therapeutics (NASDAQ:AKBA) has a recorded net income of -$51.92 million. AKBA has generated -$0.21 earnings per share over the last four quarters. What is Akebia Therapeutics's EPS forecast for next year? Akebia Therapeutics's earnings are expected to grow from ($0.30) per share to ($0.14) per share in the next year. More Earnings Resources from MarketBeat Related Companies AMRX Earnings DNLI Earnings BHVN Earnings OGN Earnings NAMS Earnings KYMR Earnings MIRM Earnings CGON Earnings TWST Earnings KNSA Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? This page (NASDAQ:AKBA) was last updated on 5/12/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon Musk’s Next Big BetCancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKBA Stock Free AKBA Stock Alerts